Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

ClinicalTrials.gov ID: NCT01296711

Public ClinicalTrials.gov record NCT01296711. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 (Olokizumab) Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056

Study identification

NCT ID
NCT01296711
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Enrollment
190 participants

Conditions and interventions

Interventions

  • CDP6038 (olokizumab) Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 6, 2011
Primary completion
Apr 30, 2013
Completion
Aug 4, 2013
Last update posted
Apr 13, 2022

2011 – 2013

United States locations

U.S. sites
50
U.S. states
24
U.S. cities
45
Facility City State ZIP Site status
166 Mesa Arizona
154 Phoenix Arizona
118 Scottsdale Arizona
103 Hot Springs Arkansas
127 Covina California
148 La Jolla California
184 Long Beach California
177 Los Angeles California
104 Palo Alto California
129 Santa Maria California
164 Upland California
141 Hamden Connecticut
111 Lewes Delaware
151 DeBary Florida
114 Jupiter Florida
157 Tampa Florida
183 Tampa Florida
116 Idaho Falls Idaho
160 Moline Illinois
168 Springfield Illinois
133 Cedar Rapids Iowa
172 Kansas City Kansas
185 Saint Clair Shores Michigan
112 St Louis Missouri
134 St Louis Missouri
102 Lincoln Nebraska
171 Freehold New Jersey
152 Toms River New Jersey
174 Brooklyn New York
170 Charlotte North Carolina
150 Cincinnati Ohio
100 Dayton Ohio
110 Oklahoma City Oklahoma
165 Duncansville Pennsylvania
105 Nashville Tennessee
135 Austin Texas
128 Dallas Texas
126 Houston Texas
132 Houston Texas
138 Houston Texas
181 Houston Texas
145 Mesquite Texas
143 Nassau Bay Texas
122 San Antonio Texas
144 Tomball Texas
142 Victoria Texas
139 Chesapeake Virginia
175 Tacoma Washington
136 Beckley West Virginia
167 Clarksburg West Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01296711, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2022 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01296711 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →